Amalgamated Bank Decreases Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Amalgamated Bank lowered its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 35,704 shares of the biopharmaceutical company’s stock after selling 4,283 shares during the quarter. Amalgamated Bank’s holdings in Dynavax Technologies were worth $398,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its position in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares in the last quarter. US Bancorp DE lifted its position in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares in the last quarter. Algert Global LLC acquired a new position in Dynavax Technologies during the 2nd quarter worth approximately $140,000. Finally, Sanctuary Advisors LLC acquired a new position in Dynavax Technologies during the 2nd quarter worth approximately $182,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of DVAX opened at $12.21 on Monday. The business’s 50 day moving average is $11.39 and its two-hundred day moving average is $11.31. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of 93.93 and a beta of 1.34. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Wall Street Analyst Weigh In

Several research firms recently commented on DVAX. The Goldman Sachs Group reduced their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.